Thrilled to be back in Boston for the AACR conference on Pancreatic Cancer and for the opportunity to present my work as an AACR Scholar in Training this evening! Find me at poster A007- I'd love to chat about all I've been working on!

#AACRpan25
@theaacr.bsky.social

Thank you!! 😃

Tumor nutrient stress gives rise to a drug tolerant cell state in pancreatic cancer Cytotoxic chemotherapy remains the standard-of-care treatment for patients with pancreatic ductal adenocarcinoma (PDAC). However, chemotherapy only has modest effects at improving patient survival due...

Super excited to share our new preprint from @cssheehan.bsky.social on how the tumor microenvironment causes drug resistance in pancreatic cancer: www.biorxiv.org/content/10.1...

Super great to work with James LaBelle’s lab on this project! And thanks to everyone involved in the study: Kay Macleod, @cjhphd.bsky.social, Alica Beutel,
@leahziolkowski.bsky.social, Mumina Sadullozoda, @patrickjonker.bsky.social, Darby Agovino, Grace Croley, @guillaumecognet.bsky.social.

Feeling incredibly grateful this week! Honored to receive the AACR Scholar-in-Training Award for the upcoming conference on Pancreatic Cancer in Boston & thrilled to get the NoA for a second year of F31 funding to continue my research on PDAC tumorigenesis in the Macleod Lab!

Tomorrow morning at AACR, I will be presenting my poster on the Integrated Stress Response in PDAC tumorigenesis! Would love to chat about what I've been working on in the Macleod Lab- find me at Section 11 (Metabolism and Signaling), Board 19 from 9am to noon!

Tumour interstitial fluid-enriched phosphoethanolamine suppresses T cell function Nature Cell Biology - Wang, Wilfahrt and colleagues show that phosphoethanolamine, a phospholipid intermediate, is enriched in tumour interstitial fluid and induces T cell dysfunction, in part by...

Excited to share new report from collaborative work from @delgoffelab.bsky.social and @patrickjonker.bsky.social from our team on a novel metabolic suppressor of T cell function in tumors! rdcu.be/eiyIa 1/

Tumor byproduct blocks immune cells from fighting cancer - UChicago Medicine Researchers from the University of Chicago and the University of Pittsburgh have identified a novel oncometabolite that accumulates in tumors and impairs immune cells’ ability to fight cancer.

🔥 Hot off the press: Researchers at the University of Chicago, in collaboration with the University of Pittsburgh, have published a groundbreaking study in @NatureCellBio demonstrating how the accumulation of a tumor metabolite impairs T cell function in the tumor microenvironment.
ow.ly/vxWI50VEJVm

Hi #metabolism #pancreaticcancer #lipidtime twitter! Excited to share @patrickjonker.bsky.social work on how the microenvironment limits the metabolic capacity of pancreatic cancers (PDAC), which sensitizes these tumors to dietary interventions. 1/17

I’m Standing Up for Science today in Chicago against the shameful, destructive, and illegal funding cuts by President Trump and Elon Musk. Researchers at National Institutes of Health find breakthrough treatments and cures. They deserve support—not attacks.

For anyone in the area, Chicago is gathering at 12PM at the Federal Plaza on March 7th to #StandUpForScience2025!